Announcement PDF Atomo Diagnostics Limited ACN 142 925 684 Level 1, 3-5 George St Leichhardt NSW 2040 ASX Announcement 27th October 2026 Atomo Q1 FY27 Quarterly Investor Webinar Presentation SYDNEY Australia, 27th October 2026 – Atomo Diagnostics Limited (ASX: AT1) (Atomo or the Company) will hold its Q1 FY27 Quarterly Investor webinar, hosted by CEO Cheri Walker & Financial Controller Suzy Elhlou on Tuesday 03rd November 2026 at 3pm (AEDT). To access the webinar please pre-register by clicking this link. We encourage you to utilise our Investor Hub for any enquiries regarding this announcement. This platform offers an opportunity to submit questions and share comments. To access Atomo’s Investor Hub please scan the QR code or visit https://investors.atomodiagnostics.com/auth/signup ~ ENDS ~ For more information, please contact: Cheri Walker CEO e. cheri.walker@atomodiagnostics.com p. +61 2 9099 4750 Investor Queries investorqueries@atomodiagnostics.com This announcement was authorised by the CEO on behalf of the Board. About Atomo Atomo is an Australian-headquartered medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market. Atomo’s unique patented devices simplify testing procedures, enhance usability and improve reliability across rapid point-of-care (POC) and at-home testing applications. The Company has successfully commercialised a number of products across international markets and has supply agreements in place for testing applications targeting infectious diseases including HIV, syphilis, liver health, viral vs bacterial differentiation and female health. See more at www.atomodiagnostics.com